Applied Biosystems Group and Celera Genomics Group Third Quarter FY 2002 Financial Results and Conference Call Scheduled for Release April 25, 2002
NORWALK, CT - April 15, 2002
Applera Corporation announced today that it will issue fiscal year 2002 third quarter results for Applied Biosystems Group (NYSE: ABI) and Celera Genomics Group (NYSE: CRA) on Thursday, April 25, 2002. Results are scheduled for release before the opening of trading on the New York Stock Exchange.
Tony L. White, Applera Corporation's chief executive officer, will lead a conference call at 10:00 a.m. (EDT) on April 25 to discuss these results and to address management's current financial outlook for the company. He will be joined by Dennis L. Winger, Applera's chief financial officer, and senior managers from Applied Biosystems and Celera Genomics, who will answer questions from securities analysts and investment professionals. Investors, securities analysts, representatives of the media and international participants who would like to participate should dial 706-634-4992 (code "applera") between 9:45 and 10:00 a.m. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit either www.applera.com and go to the Investor Relations section of the web site, or www.celera.com and go to the Investor section, or www.appliedbiosystems.com and go to the Investor Relations webpage within the "About Us" section. A digital recording will be available two hours after the completion of the conference call from April 25 to May 5, 2002. Interested parties should call (706) 645-9291 and enter Conference ID 3609219.
About Applera Corporation
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to market scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera's businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.